PGLa

PGLa is an antimicrobial peptide, synthesized in the stomach and stored in a novel granular multinucleated cell in the gastric mucosa. It is stored as active, processed peptides in large granules within the granular gland secretions of the skin. As a member of the magainin family it assumes an amphiphilic α-helical structure upon membrane binding.The cationic peptide has a high affinity for bacterial membranes and is able to permeabilize them.

PGLa is a 21-residue synthetic peptide with the sequence Gly-Met-Ala-Ser-Lys-Ala-Gly-Ala-Ile-Ala-Gly-Lys-Ile-Ala-Lys-Val-Ala-Leu-Lys-Ala-Leu. C-terminal amidation removes the terminal carboxylate charge. The sequence contains 4 Lys and 0 Arg residues, contributing cationic character; has a relatively high hydrophobic-residue fraction that can influence aqueous solubility and surface adsorption. These sequence-derived properties describe the reagent chemically; no specific receptor, enzyme, pathway, disease association, or biological activity is assigned without product-specific experimental evidence.

• LC-MS/HPLC analytical method development
• sequence-specific assay controls

Sequence-derived chemical properties support reagent selection and experimental planning but do not establish biological function. Solubility, aggregation, adsorption, conjugation efficiency, and assay performance should be validated under the intended experimental conditions.